您当前所在的位置:首页 > 产品中心 > 产品信息
Latamoxef_分子结构_CAS_64952-97-2)
点击图片或这里关闭

Latamoxef

产品号 DB04570 公司名称 DrugBank
CAS号 64952-97-2 公司网站 http://www.ualberta.ca/
分子式 C20H20N6O9S 电 话 (780) 492-3111
分子量 520.4726 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 4138

产品价格信息

请登录

产品别名

标题
Latamoxef
IUPAC标准名
(6R,7R)-7-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
IUPAC传统名
latamoxef
别名
moxalactam

产品登记号

PubChem SID 46505546
PubChem CID 47499
CAS号 64952-97-2

产品性质

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. [PubChem]
Indication Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins. It is used to treat bacterial infections. Latamoxef is primarily indicated in conditions like Bone and joint infection, GI infections, Gynecological infections, Meningitis, Respiratory tract infections, Septicaemia, Skin infections, Soft tissue infections, UTI.
Pharmacology Latamoxef works by inhibiting bacterial cell wall biosynthesis.
Toxicity Latamoxef produces potentially life-threatening effects which include Bleeding, Hypothrombinemia, Platelet dysfunctioning. which are responsible for the discontinuation of Latamoxef therapy.
The symptomatic adverse reactions produced by Latamoxef are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Skin rashes, Hematuria, Hyperuricemia, Pyuria, Raised serum creatinine.
Absorption Rapidly absorbed after oral administration.
Half Life 1.6 hours
Protein Binding 40%
Elimination Renal Excretion accounts for 75 %
Distribution 8.51 L
References
Weitekamp MR, Aber RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983 Jan 7;249(1):69-71. [Pubmed]
Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M: Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986 Nov;146(11):2159-64. [Pubmed]
External Links
Wikipedia

参考文献

  • Weitekamp MR, Aber RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983 Jan 7;249(1):69-71. Pubmed
  • Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M: Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986 Nov;146(11):2159-64. Pubmed